Step 1 topics → Hematology and Oncology → Alkylating Agents

Alkylating Agents

USMLE Step 1 trap: Incorrectly classifies alkylating agents as cell-cycle specific. Alkylating agents are cell-cycle non-specific; they cross-link DNA regardless of cell-cycle phase, which is why they are effective against slowly dividing tumors.

Alkylating agents are a broad class of chemotherapy drugs that work by covalently attaching alkyl groups to DNA, causing intrastrand and interstrand cross-links that block replication and transcription. USMLE Step 1 loves this class because the drugs share a mechanism but have clinically critical toxicity differences — and the most common wrong move is thinking hydration alone prevents hemorrhagic cystitis from cyclophosphamide. It doesn't: you need mesna to neutralize acrolein directly in the bladder. The class includes cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, cisplatin, carboplatin, and chlorambucil — each with distinct toxicity signatures the exam expects you to match to the right clinical vignette.

The exam tests this topic from two main angles: mechanism (especially cell-cycle specificity) and agent-specific toxicities with their rescue strategies. On mechanism questions, you need to know that cross-linking is the core action and that this operates independently of where the cell is in the cell cycle. On toxicity questions, expect clinical vignettes describing a patient on chemotherapy developing hematuria, pulmonary symptoms, or renal failure — and you'll need to match the toxicity to the drug and know how to prevent or treat it. USMLE Step 1 frequently pairs a drug with its unique adverse effect and asks you to identify either the mechanism of that toxicity or the appropriate prophylactic agent.

The tricky part is that students blur the toxicities together or fall back on generic 'chemotherapy causes myelosuppression and nausea' thinking. The high-yield distinctions are hemorrhagic cystitis from acrolein (cyclophosphamide/ifosfamide → prevent with mesna), pulmonary fibrosis and hyperpigmentation with busulfan, nephrotoxicity and ototoxicity with cisplatin (not carboplatin), and the unique CNS penetration of nitrosoureas. These are not obscure details — they show up repeatedly and are consistently tested.

From real student decks
89%have cards covering this topic
65%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Alkylating agents are cell-cycle specific because they damage DNA during replication.
Right: Alkylating agents are cell-cycle non-specific; they cross-link DNA regardless of cell-cycle phase, which is why they are effective against slowly dividing tumors.
Alkylating agents do not need a cell to be replicating to exert their effect — they attach alkyl groups to DNA bases (especially N7 of guanine) in any phase, including G0. This is what makes them cell-cycle non-specific. The confusion arises because DNA damage ultimately manifests during replication, but the drug acts at any time. This non-specificity is clinically important: alkylators can hit slowly cycling tumor cells that S-phase-specific drugs would miss entirely.
Common mistake
Wrong: The hemorrhagic cystitis caused by cyclophosphamide is prevented by hydration alone.
Right: Hemorrhagic cystitis from cyclophosphamide is caused by the metabolite acrolein and is prevented by mesna (which binds acrolein in urine) plus aggressive hydration.
Hydration alone is not sufficient to prevent hemorrhagic cystitis from cyclophosphamide or ifosfamide. The problem is the toxic metabolite acrolein, which accumulates in the bladder. Mesna (2-mercaptoethane sulfonate) is specifically given because it is excreted in urine where it binds and detoxifies acrolein directly. Think of mesna as a targeted chemical scavenger in the bladder — hydration dilutes the metabolite but cannot neutralize it, which is why mesna is the essential rescue agent.
Common mistake
Gap: Missing busulfan's signature toxicities of pulmonary fibrosis and hyperpigmentation
Busulfan causes pulmonary fibrosis ('busulfan lung') and hyperpigmentation in addition to myelosuppression, distinguishing it from other alkylators.
Busulfan is the outlier alkylator with two signature toxicities you won't see with other drugs in this class: pulmonary fibrosis ('busulfan lung') and diffuse hyperpigmentation of the skin. These come on top of the expected myelosuppression. When a Step 1 vignette describes a CML patient on long-term chemotherapy developing progressive dyspnea with diffuse lung infiltrates and darkening skin, busulfan is the answer. No other alkylating agent reliably produces this combination.
Common mistake
Gap: Missing that nitrosoureas are the alkylators of choice for CNS tumors due to BBB penetration
Nitrosoureas (carmustine, lomustine) are highly lipophilic and cross the blood-brain barrier, making them uniquely useful for CNS tumors among alkylating agents.
Most alkylating agents are too polar to meaningfully cross the blood-brain barrier, which limits their use against CNS tumors. Nitrosoureas — carmustine (BCNU) and lomustine (CCNU) — are highly lipophilic, which allows passive diffusion across the BBB. This makes them the alkylating agents of choice for primary brain tumors like glioblastoma. If a USMLE Step 1 question asks which chemotherapy class penetrates the CNS or is used for brain tumors, nitrosoureas is the answer within the alkylator family.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand that alkylating agents cross-link DNA in a cell-cycle non-specific manner, meaning they kill cells regardless of what phase they are in — including G0 resting cells — which distinguishes them from antimetabolites and other S-phase-specific drugs.
  2. Know the specific toxicity signature of each major alkylating agent and the corresponding rescue or prophylactic strategy: cyclophosphamide/ifosfamide cause hemorrhagic cystitis via acrolein (prevent with mesna + hydration), cisplatin causes dose-limiting nephrotoxicity and ototoxicity (prevent nephrotoxicity with aggressive saline hydration), busulfan causes pulmonary fibrosis and hyperpigmentation, and nitrosoureas cause significant myelosuppression with delayed nadir.

Can you avoid these mistakes?

A patient with ovarian cancer is being treated with cisplatin. Before starting the infusion, the oncology team administers aggressive IV saline. What toxicity does this pretreatment prevent, and what symptom would the patient develop if this prophylaxis were omitted?
A medical student argues that alkylating agents should be avoided in slowly dividing tumors because they only work during S phase. How would you correct this reasoning, and what property of alkylating agents makes them effective against low-proliferation tumors?
A 58-year-old man with a brain metastasis is being considered for systemic chemotherapy. Among the alkylating agents, which subclass would be most appropriate, and why does the pharmacokinetic property that makes them useful also explain a key toxicity consideration?
A patient receiving cyclophosphamide for lymphoma develops gross hematuria. What is the responsible metabolite, what is the first-line specific treatment or prophylactic agent, and why is IV hydration alone insufficient?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →